AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Innate Immune Response Monitoring Via Monocyte HLA-DR in Severe Intra-abdominal Infections at Risk of Fungal Infection

Recruitingn/aAges 18 Years - anyAllCentral Hospital, Nancy, France
💬

In plain words

What the trial is, and whether it could suit you

Intra-abdominal candidiasis (IAC) is a frequent and severe fungal infection in critically ill patients, often diagnosed late. Its pathophysiology remains unclear, particularly regarding why some patients develop invasive infection while others only show benign colonization. A potential explanation lies in the state of innate immunity. Monocyte HLA-DR expression, a recognized marker of immune suppression in critical care, may be transiently but profoundly reduced in non-immunocompromised patients who go on to develop IAC. This observational study aims to evaluate whether patients with IAC have greater innate immune dysfunction-assessed by HLA-DR expression-compared to those with severe bacterial intra-abdominal infections. The goal is to better understand the immune mechanisms involved and improve early risk stratification for IAC.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Adult patient (≥ 18 years old) * Patient admitted to the ICU or intermediate care unit for a severe intra-abdominal infection requiring urgent abdominal surgery * Presence of at least one risk factor for intra-abdominal candidiasis: * Abdominal surgery within the last 7 days * Supramesocolic gastrointestinal perforation * Healthcare-associated intra-abdominal infection * Community-acquired intra-abdominal infection in an immunocompromised patient\* * Intra-abdominal infection complicated by septic shock * Broad-spectrum antibiotic exposure within 72 hours prior to surgery * And/or a Peritonitis Score ≥ 3 out of 4 * Patient affiliated with or benefiting from a national health insurance system * Patient who has received full information about the clinical study Exclusion Criteria: * Radiologically guided drainage without surgery * Infected acute pancreatitis * Limitation or withdrawal of life-sustaining treatments * Moribund patient with an expected life expectancy \< 48 hours * Woman of childbearing potential without effective contraception * Refusal to participate in the study
💊

What it tests

  • Immunomonitoring
📍

Where

1 site
CHRU de NANCY
Vandœuvre-lès-Nancy, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy